Evidence map›Paper›PMID 42519394›Full record

ArticleMolecular therapy. Oncology2026

Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner.

Lorenz Hanesch, Nina Hartmann, Sonja Glauß, Tianle Feng, Jennifer Altomonte

Abstract read
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lorenz HaneschTUM School of Medicine and Health - Clinical Department of Internal Medicine II, TUM University Hospital, Munich, Germany.
Nina HartmannTUM School of Medicine and Health - Clinical Department of Internal Medicine II, TUM University Hospital, Munich, Germany.
Sonja GlaußTUM School of Medicine and Health - Clinical Department of Internal Medicine II, TUM University Hospital, Munich, Germany.
Tianle FengTUM School of Medicine and Health - Clinical Department of Internal Medicine II, TUM University Hospital, Munich, Germany.
Jennifer AltomonteTUM School of Medicine and Health - Clinical Department of Internal Medicine II, TUM University Hospital, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, activation of the immune system has been recognized as a key mechanism in supporting the therapeutic outcome of oncolytic virotherapy for cancer. Most studies have focused on T cells in the characterization of immune responses to therapy; however, the role of dendritic cells (DCs) in priming these cytotoxic T cell responses has been far less explored. rVSV-NDV is a chimeric oncolytic virus that causes a highly immunogenic cell death in infected tumor cells. In tumor-bearing mice, this leads to increased levels of circulating and tumor-infiltrating tumor-specific CD8

Indexed as

cancer immunotherapycancer vaccinedendritic cellimmunogenic cell deathoncolytic virus

Identifiers

PMID42519394
PMCPMC13382584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.